{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:34:40Z","timestamp":1791588880330,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.intimp.2025.115834","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T22:04:07Z","timestamp":1763417047000},"page":"115834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P1","title":["Ticagrelor attenuates cholestasis-induced liver fibrosis by inhibiting S1PR2-dependent Akt\/ERK signaling, NLRP3 inflammasome activation"],"prefix":"10.1016","volume":"168","author":[{"given":"Walaa H.","family":"El-Maadawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Amer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman A.","family":"Hassany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesma S.","family":"Shafie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed W.","family":"Lethy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"El-Ahwany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehab","family":"Hafiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.115834_bb0005","doi-asserted-by":"crossref","first-page":"581","DOI":"10.14218\/JCTH.2023.00519","article-title":"Progress in the Management of Patients with cholestatic liver disease: where are we and where are we going?","volume":"12","author":"Luo","year":"2024","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.intimp.2025.115834_bb0010","doi-asserted-by":"crossref","first-page":"757","DOI":"10.14218\/JCTH.2022.00147","article-title":"Guidelines for the Management of Cholestatic Liver Diseases (2021)","volume":"10","author":"Lu","year":"2022","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.intimp.2025.115834_bb0015","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00281-022-00935-7","article-title":"Bile acids and their receptors: modulators and therapeutic targets in liver inflammation","volume":"44","author":"Bertolini","year":"2022","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.intimp.2025.115834_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2020.111133","article-title":"Inflammation: cause or consequence of chronic cholestatic liver injury","volume":"137","author":"Woolbright","year":"2020","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.intimp.2025.115834_bb0025","doi-asserted-by":"crossref","first-page":"882","DOI":"10.2478\/s11686-020-00230-1","article-title":"Prevalence of Cryptosporidium infection in the global population: a systematic review and Meta-analysis","volume":"65","author":"Dong","year":"2020","journal-title":"Acta Parasitol."},{"key":"10.1016\/j.intimp.2025.115834_bb0030","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1021\/acs.jproteome.5b00217","article-title":"Serum bile acids are associated with pathological progression of hepatitis B-induced cirrhosis","volume":"15","author":"Wang","year":"2016","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.intimp.2025.115834_bb0035","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202201954R","article-title":"Liver sinusoidal endothelial S1pr2 regulates experimental liver fibrosis through YAP\/TGF-\u03b2 signaling pathway","volume":"37","author":"Liao","year":"2023","journal-title":"FASEB J."},{"key":"10.1016\/j.intimp.2025.115834_bb0040","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.livres.2017.03.002","article-title":"Bile acids as global regulators of hepatic nutrient metabolism","volume":"1","author":"Hylemon","year":"2017","journal-title":"Liver Res."},{"key":"10.1016\/j.intimp.2025.115834_bb0045","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.livres.2019.02.003","article-title":"Sphingosine-1-phosphate signaling and the gut-liver axis in liver diseases","volume":"3","author":"Kwong","year":"2019","journal-title":"Liver Res."},{"key":"10.1016\/j.intimp.2025.115834_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2024.101101","article-title":"Bile acids attenuate hepatic inflammation during ischemia\/reperfusion injury","volume":"6","author":"Huang","year":"2024","journal-title":"JHEP Reports."},{"key":"10.1016\/j.intimp.2025.115834_bb0055","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/hep.24681","article-title":"Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes","volume":"55","author":"Studer","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.intimp.2025.115834_bb0060","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.29076","article-title":"The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice","volume":"65","author":"Wang","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.intimp.2025.115834_bb0065","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1194\/jlr.R069286","article-title":"The roles of bile acids and sphingosine-1-phosphate signaling in the hepatobiliary diseases","volume":"57","author":"Nagahashi","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.intimp.2025.115834_bb0070","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00109-020-02032-4","article-title":"NLRP3 inflammasome priming and activation in cholestatic liver injury via the sphingosine 1-phosphate\/S1P receptor 2\/g\u03b1(12\/13)\/MAPK signaling pathway","volume":"99","author":"Hou","year":"2021","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.intimp.2025.115834_bb0075","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3350\/cmh.2022.0327","article-title":"Taurocholic acid promotes hepatic stellate cell activation via S1PR2\/p38 MAPK\/YAP signaling under cholestatic conditions","volume":"29","author":"Yang","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.intimp.2025.115834_bb0080","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J. Hepatol."},{"issue":"2019","key":"10.1016\/j.intimp.2025.115834_bb0085","first-page":"394","article-title":"Practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2018","journal-title":"Hepatology"},{"issue":"2014","key":"10.1016\/j.intimp.2025.115834_bb0090","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1161\/CIR.0000000000000133","article-title":"AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.intimp.2025.115834_bb0095","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jval.2013.01.013","article-title":"Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial","volume":"16","author":"Levin","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.intimp.2025.115834_bb0100","article-title":"Repurposing a platelet aggregation inhibitor ticagrelor as an antimicrobial against Clostridioides difficile","volume":"10","author":"Phanchana","year":"2020","journal-title":"Sci. Reports"},{"key":"10.1016\/j.intimp.2025.115834_bb0105","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2174\/1874467214666210204212533","article-title":"Ticagrelor ameliorates bleomycin-induced pulmonary fibrosis in rats by the inhibition of TGF-\u03b21\/Smad3 and PI3K\/AKT\/mTOR pathways","volume":"15","author":"Wanas","year":"2022","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.intimp.2025.115834_bb0110","article-title":"Ticagrelor, but not clopidogrel, attenuates hepatic steatosis in a model of metabolic dysfunction-associated Steatotic liver disease","volume":"16","author":"Lee","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.intimp.2025.115834_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216260","article-title":"Dual antiplatelet therapy inhibits neutrophil extracellular traps to reduce liver micrometastases of intrahepatic cholangiocarcinoma","volume":"567","author":"Yoshimoto","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2025.115834_bb0120","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/hep4.1254","article-title":"Use of antiplatelet agents is inversely associated with liver fibrosis in patients with cardiovascular disease","volume":"2","author":"Schwarzkopf","year":"2018","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.intimp.2025.115834_bb0125","article-title":"Structure of S1PR2\u2013heterotrimeric G13 signaling complex","volume":"8","author":"Chen","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.intimp.2025.115834_bb0130","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock Vina 1.2.0: new docking methods, expanded force field, and Python bindings","volume":"61","author":"Eberhardt","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.intimp.2025.115834_bb0135","doi-asserted-by":"crossref","first-page":"D1405","DOI":"10.1093\/nar\/gkac1033","article-title":"An integrated resource for the understudied human proteome","volume":"51","author":"Kelleher","year":"2023","journal-title":"Nucleic Acids Res."},{"issue":"2025","key":"10.1016\/j.intimp.2025.115834_bb0140","doi-asserted-by":"crossref","first-page":"D1516","DOI":"10.1093\/nar\/gkae1059","article-title":"PubChem","volume":"53","author":"Kim","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.intimp.2025.115834_bb0145","doi-asserted-by":"crossref","DOI":"10.3791\/52438-v","article-title":"Bile duct ligation in mice: induction of inflammatory liver injury and fibrosis by obstructive cholestasis","author":"Tag","year":"2015","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.intimp.2025.115834_bb0150","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bcp.2019.06.009","article-title":"Anticholestatic mechanisms of ursodeoxycholic acid in lipopolysaccharide-induced cholestasis","volume":"168","author":"Razori","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.intimp.2025.115834_bb0155","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"10.1016\/j.intimp.2025.115834_bb0160","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u0394\u0394CT method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.intimp.2025.115834_bb0165","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.16744","article-title":"Reversal of cholestatic liver disease by the inhibition of sphingosine 1-phosphate receptor 2 signaling","volume":"12","author":"Cao","year":"2024","journal-title":"Peer J"},{"key":"10.1016\/j.intimp.2025.115834_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11306-022-01906-7","article-title":"Roles of ursodeoxycholic acid in the bile biochemistry and metabolomics in patients with choledocholithiasis: a prospective study","volume":"18","author":"Guan","year":"2022","journal-title":"Metabolomics"},{"key":"10.1016\/j.intimp.2025.115834_bb0175","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s40265-020-01427-4","article-title":"Pralsetinib: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2025.115834_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107723","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2025 update","volume":"216","author":"Roskoski","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2025.115834_bb0185","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(09)62191-7","article-title":"Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study","volume":"375","author":"Cannon","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2025.115834_bb0190","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2025.115834_bb0195","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2025.115834_bb0200","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2025.115834_bb0205","doi-asserted-by":"crossref","first-page":"G460","DOI":"10.1152\/ajpgi.00127.2023","article-title":"Hepatic LGR4 aggravates cholestasis-induced liver injury in mice","volume":"326","author":"Gao","year":"2024","journal-title":"Am. J. Physiol. - Gastrointest. Liver Physiol."},{"key":"10.1016\/j.intimp.2025.115834_bb0210","first-page":"1254","article-title":"Animal models of biliary injury and altered bile acid metabolism","volume":"2018","author":"Mariotti","year":"1864","journal-title":"Biochim. Biophys. Acta - Mol. Basis Dis."},{"key":"10.1016\/j.intimp.2025.115834_bb0215","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/sji.12395","article-title":"Neutralization of Interleukin-17 attenuates cholestatic liver fibrosis in mice","volume":"83","author":"Zhang","year":"2016","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.intimp.2025.115834_bb0220","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/j.2040-4603.2022.tb00205.x","article-title":"Bile acids, gut microbiome and the road to fatty liver disease","volume":"12","author":"Hylemon","year":"2022","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.intimp.2025.115834_bb0225","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pharmthera.2018.02.011","article-title":"Inflammasome biology, molecular pathology and therapeutic implications","volume":"187","author":"Awad","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2025.115834_bb0230","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-\u03b2","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol. Cell"},{"key":"10.1016\/j.intimp.2025.115834_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01149","article-title":"Macrophage sphingosine 1-phosphate receptor 2 blockade attenuates liver inflammation and fibrogenesis triggered by NLRP3 inflammasome","volume":"11","author":"Hou","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115834_bb0240","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jcmgh.2019.12.008","article-title":"Inflammasome is activated in the liver of cholestatic patients and aggravates hepatic injury in bile duct-ligated mouse","volume":"9","author":"Cai","year":"2020","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2025.115834_bb0245","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2025.115834_bib248","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.178182","article-title":"Forskolin alleviates cholestatic liver disease by inhibiting the Hippo\/YAP-mediated ductular reaction and fibrosis progression","volume":"1006","author":"El-Maadawy","year":"2025","journal-title":"Eur. J. Pharmacol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925018223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925018223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T19:41:03Z","timestamp":1781898063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925018223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":50,"alternative-id":["S1567576925018223"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115834","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ticagrelor attenuates cholestasis-induced liver fibrosis by inhibiting S1PR2-dependent Akt\/ERK signaling, NLRP3 inflammasome activation","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115834","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115834"}}